EP1003514A4 - Cyclic amine modulators of chemokine receptor activity - Google Patents

Cyclic amine modulators of chemokine receptor activity

Info

Publication number
EP1003514A4
EP1003514A4 EP98936920A EP98936920A EP1003514A4 EP 1003514 A4 EP1003514 A4 EP 1003514A4 EP 98936920 A EP98936920 A EP 98936920A EP 98936920 A EP98936920 A EP 98936920A EP 1003514 A4 EP1003514 A4 EP 1003514A4
Authority
EP
European Patent Office
Prior art keywords
modulators
chemokine receptor
receptor activity
cyclic amine
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98936920A
Other languages
German (de)
French (fr)
Other versions
EP1003514A1 (en
Inventor
Charles G Caldwell
Paul E Finke
Malcolm Maccoss
Laura C Meurer
Sander G Mills
Bryan Oates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800958.2A external-priority patent/GB9800958D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1003514A1 publication Critical patent/EP1003514A1/en
Publication of EP1003514A4 publication Critical patent/EP1003514A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
EP98936920A 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity Withdrawn EP1003514A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5375497P 1997-07-25 1997-07-25
US53754P 1997-07-25
GBGB9800958.2A GB9800958D0 (en) 1998-01-16 1998-01-16 Cyclic amine modulators of chemokine activity
GB9800958 1998-01-16
PCT/US1998/014990 WO1999004794A1 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
EP1003514A1 EP1003514A1 (en) 2000-05-31
EP1003514A4 true EP1003514A4 (en) 2000-10-11

Family

ID=26312958

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98936920A Withdrawn EP1003514A4 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity

Country Status (5)

Country Link
EP (1) EP1003514A4 (en)
JP (1) JP2002510327A (en)
AU (1) AU8576098A (en)
CA (1) CA2296314A1 (en)
WO (1) WO1999004794A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
JP3475177B2 (en) * 1998-11-17 2003-12-08 エフ．ホフマン−ラ ロシュ アーゲー 4-Aroylpiperidine CCR-3 receptor antagonist III
EP1140834A1 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
EP1158980B1 (en) 1998-12-18 2005-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140087A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CA2368047A1 (en) 1999-03-24 2000-09-28 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2371618A1 (en) * 1999-04-28 2000-11-09 Yuji Ishihara Cyclic amide compounds, their production and use
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
DK1175401T3 (en) * 1999-05-04 2005-11-14 Schering Corp Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
IL145742A0 (en) * 1999-05-04 2002-07-25 Schering Corp Piperidine derivatives useful as ccr5 antagonists
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
WO2000076514A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
JP4688381B2 (en) * 1999-06-11 2011-05-25 メルク・シャープ・エンド・ドーム・コーポレイション N-cyclopentyl modulator of chemokine receptor activity
WO2000076511A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6500844B1 (en) 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2000076513A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2000076973A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
AR025884A1 (en) 1999-10-01 2002-12-18 Takeda Pharmaceutical CYCLINE AMINE COMPOUNDS, ITS PRODUCTION AND USE
CA2386387A1 (en) 1999-10-05 2001-04-12 Takeda Chemical Industries, Ltd. Urea compounds, their production and use
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
SI1284974T1 (en) * 2000-05-26 2004-08-31 Pfizer Inc. Triazolyl tropane derivatives as ccr5 modulators
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
MXPA02012712A (en) 2000-06-30 2003-04-25 Bristol Myers Squibb Pharma Co N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
TWI227231B (en) 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
AU2002230665A1 (en) 2000-12-06 2002-06-18 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
KR100613528B1 (en) 2001-03-29 2006-08-16 쉐링 코포레이션 CCR5 Antagonists, and a pharmaceutical composition and a kit comprising the same
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
SE0101322D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
BR0210733A (en) 2001-07-02 2004-07-20 Astrazeneca Ab Useful piperidine derivatives useful as modulators of chemokine receptor activity
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
TW200305395A (en) * 2002-03-15 2003-11-01 Novartis Ag Organic compounds
SE0200844D0 (en) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (en) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
CN101092401A (en) * 2002-03-29 2007-12-26 先灵公司 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
TW200409630A (en) 2002-09-12 2004-06-16 Bristol Myers Squibb Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
MXPA05006354A (en) 2002-12-13 2005-08-26 Smithkline Beecham Corp Piperidine derivatives as ccr5 antagonists.
TWI344955B (en) * 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
CA2520225C (en) 2003-03-24 2014-08-12 Bayer Healthcare Ag Benzenesulfonamide derivatives
SE0300957D0 (en) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidine compound and medicinal use thereof
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
BRPI0411131A (en) 2003-06-11 2006-07-18 Merck & Co Inc compound, method of treating a cannabinoid receptor-mediated disease 1, method of preventing obesity in a person at risk for obesity, composition, and use of a compound
PL1663966T3 (en) * 2003-09-15 2007-11-30 Novartis Ag 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
SE0400208D0 (en) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
JPWO2006129679A1 (en) 2005-05-31 2009-01-08 小野薬品工業株式会社 Spiropiperidine compounds and pharmaceutical uses thereof
US7790747B2 (en) * 2005-06-15 2010-09-07 Genzyme Corporation Chemokine receptor binding compounds
KR20080037655A (en) 2005-07-21 2008-04-30 아스트라제네카 아베 Novel piperidine derivatives
ES2427989T3 (en) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compound containing a basic group and its use
WO2007058322A1 (en) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US8003642B2 (en) 2006-03-10 2011-08-23 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2456309B1 (en) 2009-07-24 2015-12-23 GlaxoSmithKline LLC Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV.
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
ES2907489T3 (en) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Cancer treatment methods
CN109069486A (en) 2015-12-14 2018-12-21 X4 制药有限公司 The method for the treatment of cancer
CA3009176A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
JP2019510785A (en) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド How to treat cancer
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
CN109640988A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
JP6994767B2 (en) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110483490B (en) * 2019-08-29 2023-02-03 苏州汉德创宏生化科技有限公司 Synthesis method of 3- (piperidine-4-yl) oxazolidine-2-ketone and salt thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494717A1 (en) * 1991-01-10 1992-07-15 Shell Internationale Researchmaatschappij B.V. Piperidine derivatives
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
EP0673928A1 (en) * 1994-03-18 1995-09-27 Sanofi Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494717A1 (en) * 1991-01-10 1992-07-15 Shell Internationale Researchmaatschappij B.V. Piperidine derivatives
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
EP0673928A1 (en) * 1994-03-18 1995-09-27 Sanofi Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9904794A1 *

Also Published As

Publication number Publication date
CA2296314A1 (en) 1999-02-04
EP1003514A1 (en) 2000-05-31
AU8576098A (en) 1999-02-16
JP2002510327A (en) 2002-04-02
WO1999004794A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
EP1003514A4 (en) Cyclic amine modulators of chemokine receptor activity
EP1140086A4 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1171122A4 (en) Pyrrolidine modulators of chemokine receptor activity
EP1003743A4 (en) 3,3-disubstituted piperidines as modulators of chemokine receptor activity
EP1173170A4 (en) Pyrrolidine modulators of chemokine receptor activity
EP1009405A4 (en) Pyrrolidine and piperidine modulators of chemokine receptor activity
AU5522498A (en) Substituted aryl piperazines as modulators of chemokine receptor activity
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HK1054032A1 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
AU2056800A (en) Heterocyclic piperidines as modulators of chemokine receptor activity
AU4074200A (en) Pyrrolidine modulators of chemokine receptor activity
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
IL135488A0 (en) Cyclic amine derivatives
PL336793A1 (en) Modulators of a stimulated acid receptor
AU5600100A (en) Cyclopentyl modulators of chemokine receptor activity
AU5812498A (en) Substituted aminoquinolines as modulators of chemokine receptor activity
AU1201401A (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
MXPA03008109A (en) Modulators of chemokine receptor activity.
AU4201200A (en) Pyrrolidine modulators of chemokine receptor activity
AU3386500A (en) 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
EP1558250A4 (en) Gamma-aminoamide modulators of chemokine receptor activity
AU2002241724A1 (en) Diamines as modulators of chemokine receptor activity
EP1558253A4 (en) Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
AU3389300A (en) Pyrrolidine modulators of chemokine receptor activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000225

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000829

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A, 7C 07D 401/06 B, 7C 07D 211/14 B, 7C 07D 409/06 B, 7C 07D 403/04 B, 7C 07D 413/04 B, 7A 61K 31/535 B, 7C 07D 407/04 B, 7C 07D 401/04 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020201